Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients

Inclusion Criteria: * HIV-1 infection, confirmed by a western-blot assay, at least 6 months after primary infection * Age \> or equal to 18 years of age * No prior antiretroviral treatment * Karnofsky superior to 60% * CD4 T cells \< 350/µL (2 measures, with at least a 1-month interval) in women, study will be proposed when CD4 cell count is below 250/µL, as nevirapine liver toxicity increases (X10) when CD4 are \> 250/µL * Written informed consent Exclusion Criteria: * HIV-2 infection or co-infection * Prior antiretroviral treatment * Intolerance, or contraindication to investigational drugs * Pregnant or breast-feeding woman, or plan to become pregnant * Active untreated opportunistic infections (AIDS-defining illness, category C, CDC, 1993), or malignancies requiring cytotoxic chemotherapy * Biological criteria: hemoglobin \< 10 G/DL, neutrophil count \< 1000/µL, platelets \< 50000/µL, creatinine \> 2N, ASAT or ALAT \> 2.5N, bilirubin \> 2N, hypophosphatemia * Prevision of poor adherence * HBC co-infection (Ag Hbs positive) or HVC co-infection (positive HCV PCR) * Liver failure, alcohol abuse * Treatment administration not recommended with investigational drugs * Interferon, interleukin, or HIV vaccine treatment * Informed consent not obtained